Bone Abstracts

see P410....

Background: On cessation of bisphosphonate treatment, while bone mineral density decreases slowly, bone resorptive markers such as C-terminal telopeptide (CTX) increase more quickly and may be useful in monitoring ‘offset’ of action. Our aim was to analyse changes in CTX on stopping long-term bisphosphonate treatment to guide clinical decision-making on the duration of treatment cessation (‘drug holidays’).Subjects and methods: A tota...

Introduction: Intravenous bisphosphonates (IB) and subcutaneous denosumab (SD) are potent antiresorptive agents widely used in the treatment of osteoporosis, Paget’s disease and metastatic malignancy. Several case reports have identified the risk of life-threatening hypocalcaemia with these treatments, particularly in the context of vitamin D deficiency and further highlighted by recent UKMHRA advice.Design: To optimise vitamin D status and decrease...

There is wide variation in the dose-response to oral vitamin D and the increment in plasma 25(OH)D decreases per unit vitamin D given. We hypothesised that this is related to increased 25(OH)D catabolism as reflected in 25OHD half-life (25(OH)D3 t1/2).Design: 25(OH)D3 t1/2 was measured with a stable isotope (SI) technique in older (70y+) men and women in the UK during winter before (<...

see P221b....

Background, subjects and methods: Vitamin D insufficiency in older people in the UK is common and may cause secondary hyperparathyroidism and bone loss. In a randomised, double blind intervention trial to optimise “Vitamin D status in Older People’ (VDOP) three oral dosages of vitamin D3 (12 kIU, 24 kIU or 48 kIU/month) were given for 12 months to 375 participants aged over 70 years (ANOVA) adjustment for covariables with results below presented in ascendi...

see PP385....

Introduction: Fracture risk assessment using FRAX® estimates 10-year fracture risk (FR10) at major sites (Maj_FR10) and hip (Hip_FR10). In 2012, in Newcastle, UK, a strategy was agreed to share data between General Practice (GP), Clinical Commissioning Groups and local hospitals to identify patients at high FR10.Methods/design: FRAX® and RAID® (a health reporting, analysis and intelligence delive...